The American Physiological Society gratefully acknowledges the services of the following reviewers who assisted the Editorial Board in the reviews of manuscripts.

Abraham, Nader G.
Acott, Ted
Addabbo, Francesco
Akbarali, Hamid I.
Albertoni Borghese, Maria F.
Alevriadou, B. R.
Allen, David L.
Allen, Paul D.
Allen, Ronald E.
Alper, Seth L.
Alrefai, Waddah A.
Alway, Stephen E.
Andrade, Francisco H.
Andrade, Rodrigo
Andresen, Bradley T.
Andresen, Michael C.
Annunziato, Lucio
Anwer, M. Sawkat
Aoi, Wataru
Apodaca, Gerard
Apostolov, Eugene O.
Arcangeli, Annarosa
Ardehali, Hossein
Arguello, Jose
Badaut, Jerome
Baer, Harald
Balaban, Robert S.
Barber, Diane L.
Barnes, Steven
Barrett, Kim E.
Bear, Christine
Beck, Laurent
Beech, David J.
Beierwaltes, William H.
Bennett, Vann
Bernard, Daniel
Bers, Donald M.
Beyenbach, Klaus W.
Bikle, Daniel D.
Bird, Ian M.
Biswa, Roopa
Blauw, Bert
Black, Stephen M.
Blaine, Judith
Bobulescu, Ion A.
Bodine, Sue C.
Boerma, Marjan
Bogorad, Roman L.
Bolotina, Victoria M.
Bonnet, Sebastien
Booth, Frank W.
Borges, Ricardo
Borkan, Steven C.
Bost, Frédéric
Boudina, Sihem
Bouillaud, Frederic
Bouyer, Patrice
Bradbury, Neil A.
Breen, Ellen C.
Breitwieser, Gerda E.
Breslin, Jerome W.
Brodky, Sergey V.
Brown, Dennis
Browning, Kirsteen N.
Brozovich, Frank V.
Bussolati, Ovidio
Butler, Peter J.
Ca, Hua Linda
Cai, Lu
Cantia, Oscar A.
Canessa, Cecilia M.
Cannell, Mark B.
Cao, Weibiao
Carbone, Emilio
Carrol, John L.
Chacko, Samuel
Chan, Lawrence
Chase, P. B.
Chazaud, Bénédicte
Chen, Jie
Chen, Jun
Chen, Xuequn
Chen, Yuqing
Cherubini, Enrico
Chiamvimonvat, Nipavan
Chimini, Giovanna
Cho, Chi H.
Chou, Chung-Lin
Church, Frank
Cidlowski, John A.
Civan, Mortimer M.
Clark, Edlira B.
Cogno, Patrice
Cohen, David M.
Cole, William C.
Colgan, Sean
Collins, James F.
Conrad, Kirk P.
Considine, Robert V.
Cooper, Arthur J.
Corriden, Ross
Creighton, Judy
Cribbs, Leanne L.
Croft, Kevin
Cunningham, J. T.
Cunningham, Rochelle
Cuppoletti, John
Czaja, Mark J.
Dahl, Gerhard P.
Davis, Paul J.
Davis, Robin L.
Davis, Teresa A.
Dawson, David C.
De Lisle, Robert C.
Dean, David A.
Delafontaine, Patrice
DeLuca, Hector F.
Diehl, Anna Mae
Diez, Javier
DiMario, Joseph
Dixon, Dan A.
Dixon, Ian M.
Djangoz, Mustafa
Donaldson, Paul J.
Donowitz, Mark
Drain, Peter
Drews, Gisela
Dubayk, George R.
Dudek, Steven M.
Dudley, Samuel C.
Duffy, Michael E.
Dumont, J.E.
Dupont-Versteegden, Esther E.
Earley, Scott
Earm, Y.E.
Eaton, Douglas C.
Edwards, John G.
Eguchi, Satoru
Ehrhart-Bornstein, Monika
Eide, David J.
Elis, Peter
Emala, Charles W.
Enns, Caroline A.
Epshtein, Yulia
Escobar, Jeffery
Evans, Roger G.
Everett, Allen D.
Ewing, Andrew
Farrugia, Gianrico
Fejerskov, Ole
Ficker, Eckhard
Fingar, Diane C.
Firth, Amy L.
Fischer, Horst
Fisher, Aron B.
Flück, Martin
Fleming, Ingrid
Fong, Peking
Forster, Ian C.
Fox, Aaron P.
Franken, Sebastian
Frey, Mark R.
Fritzsche, Bernd
Fromy, Berengere
Fuller, Catherine M.
Furue, Miho K.
Gaestel, Matthias
Gao, Bin
Geibel, John P.
Gelato, Marie C.
Gensch, Thomas
Gerthoffer, William T.
Girardi, Adriana C.
Glass, Michelle
Goldman, Jeremy
Goncharova, Elena A.
Gong, Xiaohua
Gottardi, Cara J.
Gottlieb, Roberta A.
Greenberg, Robert M.
Greenwood, Iain A.
Grichtchenko, Irina I.
Grillari, Johannes
Groblewski, Guy E.
Grunnet, Morten
Gu, Qihai
Guo, Zhenheng
Gutwein, Paul
Haller, Hermann
Hamilton, Kirk L.
Hamilton, Thomas A.
Handschin, Christoph
Hardeman, Edna C.
Hardin, Christopher D.
Harper, Richard W.
Hasselgren, Per-Olof
Hawke, Thomas J.
Heilig, Charles W.
Heiny, Judith A.
Helms, My N.
<table>
<thead>
<tr>
<th>Thompson, Linda F.</th>
<th>Verstraeten, Sandra V.</th>
<th>Widdicombe, Jonathan H.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiidus, Peter M.</td>
<td>Vestweber, Dietmar</td>
<td>Wieczorek, David F.</td>
</tr>
<tr>
<td>Tiruppathi, Chinnaswamy</td>
<td>Viguerie, Nathalie</td>
<td>Wilkie, Thomas</td>
</tr>
<tr>
<td>Toews, Myron L.</td>
<td>Villalobo, Antonio</td>
<td>Wilkins, Robert J.</td>
</tr>
<tr>
<td>Trappe, Todd A.</td>
<td>Wagner, Carsten A.</td>
<td>Wolin, Michael S.</td>
</tr>
<tr>
<td>Trebak, Mohamed</td>
<td>Wang, Jian-Ying</td>
<td>Wondergem, Robert</td>
</tr>
<tr>
<td>Tseng, Gea-Ny</td>
<td>Wang, Wen-Hui</td>
<td>Wong, Tak M.</td>
</tr>
<tr>
<td>Urban, Jill</td>
<td>Wang, Xuejun</td>
<td>Wright, David C.</td>
</tr>
<tr>
<td>Ushio-Fukai, Masuko</td>
<td>Ward, Sean M.</td>
<td>Wright, David C.</td>
</tr>
<tr>
<td>Vallon, Volker</td>
<td>Weaver, Timothy E.</td>
<td>Wu, Yuejin</td>
</tr>
<tr>
<td>Vandenberg, Carol</td>
<td>Weisman, Gary A.</td>
<td>Xavier, Sandhya</td>
</tr>
<tr>
<td>Vendelin, Marko</td>
<td>Wells, Sam</td>
<td>Xing, Michael Mingzhao</td>
</tr>
<tr>
<td>Verhaar, Marianne C.</td>
<td>Wettwer, Erich</td>
<td>Xu, Qingbo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yaksh, Tony L.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yan, Zhen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yu, Alan S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yu, Shan Ping</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yuan, Sarah Y.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zasloff, Michael</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zhou, Huiping</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ziche, Marina</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zick, Yehiel</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zoukhri, Driss</td>
</tr>
</tbody>
</table>
The American Physiological Society: 
Instructions for Preparing Your Manuscript

This document will take you through all the major steps of preparing your manuscript for submission to the American Physiological Society Journals. The full, HTML version of these Instructions is located at http://www.the-aps.org/publications/authorinfo, and is linked to additional information on PDFs, image file formats, etc.

These instructions pertain to all of the American Journal of Physiology sections, as well as the Journal of Applied Physiology, the Journal of Neurophysiology, and Physiological Genomics. Please note that Advances in Physiology Education, Physiology (invited only), and Physiological Reviews (invited only) have specific instructions that you should review if you are submitting to them.

The American Physiological Society (APS) Journals seek definitive papers that present the entire contents of a research project. In general, all data from a group of subjects, animals, or samples should be presented together in a single paper. If this cannot be done, then the manuscript should be cross-referenced. Identical subject, animal, and sample numbers should be used in the different manuscripts to identify their commonality.

Disclaimer

The statements and opinions contained in the articles of the APS journals are solely those of the individual authors and contributors and not of the APS. The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or their safety. The APS disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in any article or advertisement.

Ethical Policies

For the complete details of the APS Ethical Policies, go to http://www.the-aps.org/publications/authorinfo. All potential authors should read and understand these policies before proceeding with submission of an article to any APS publication. The complete Ethical Policies are also available at the end of this document.

Peer Review Policy

Manuscripts are refereed critically by two or more reviewers. Acceptance of manuscripts is based on scientific content and presentation of the material; membership in the Society is not a prerequisite for publication. The Editor/Associate Editor selects the reviewers, corresponds with the author, and makes the final decision on the acceptance or rejection of the manuscript.

If a manuscript is submitted by an Editor of the Journal, another Editor handles that manuscript. The APS Peer Review office helps ensure confidentiality by blinding user records in the system to be used for this purpose.

If an article is accepted by the Editor, it will be processed by the Peer Review Department, and authors are required to resolve any outstanding issues before the article is moved into production. Once an article is in production, it will be posted to the APS publish-ahead-of-print site (“Articles in Press”) in manuscript form (excluding Letters to the Editor), and the manuscript files will be moved to the Editorial department for production in final form, to be included in the next possible upcoming monthly issue. Once an article is in production, authors may not request an arbitrary delay without the consent of the Editor.

Copyright

The Mandatory Submission Form serves as the Society’s official copyright transfer form. (Forms customized to your manuscript are available on completion of the submission process; check the Info Page of the journal to which you are submitting, for blank forms: http://www.the-aps.org/publications/journals/index.htm.) The APS Journals are copyrighted for the protection of authors and the Society.

Permissions Policy

To reproduce previously published materials for which permission is required (authors re-using material as indicated below, or non-authors reusing any APS material), please use our Permissions Request Form available from the APS website (http://www.the-aps.org/publications/authorinfo). Permission to reproduce previously published material is restricted to the final-published version of an article.

APS articles may be reproduced within the bounds of the US Copyright Law. In many cases, a per-copy fee may be required, which can be paid through the Copyright Clearance Center, Inc. 222 Rosewood Dr., Danvers, MA 01923 (www.copyright.com).

Rights of Authors for APS Articles

For educational purposes only, authors may make copies of their own articles or republish parts of these articles (e.g., figures, tables), without charge and without requesting permission, provided that full acknowledgement of the source is given in the new work. Also, authors may e-mail a PDF of their article to fellow researchers for educational purposes. However, authors may not post a PDF of their published article on any website; instead, links may be posted to the article on the APS Journal website. Posting of articles or parts of articles is restricted and subject to the conditions below.

Rights of Authors for Reuse of Content from Their Articles

Theses and dissertations. APS permits whole published articles to be reproduced without charge in dissertations, which may be posted to theses repositories. Full citation is required.

Open courseware. Articles, or parts of articles, may be posted to a public access courseware website. Permission must be requested from the APS. A copyright fee will apply during the first 12 months of the article’s publication by the APS. The APS requires full citation for all permissions granted.

Institutional websites. The author’s published article (whether in whole or in part) may be posted to an institutional website, neither at the institutional nor departmental level. This exclusion includes, but is not limited to, library websites and national government websites. Instead, a link to the article on the APS journal website should be used. (see also the APS Policy on Funding Agencies, below).

Institutional repositories (non-theses). The author's published article (whether in whole or in part) may not be posted to any institutional repository. This exclusion includes, but is not limited to, library repositories and national government repositories. Instead, a link to the APS journal website should be used. (see also the APS Policy on Funding Agencies, below)

Author’s article in presentations. Authors may use their articles (whether in whole or in part) for presentations (e.g., at meetings and conferences). These presentations may be reproduced (e.g., in monographs) on any type of media including, but not limited to, CDs, DVDs, and flash drives, for educational use only in materials arising from the meeting or conferences such as the proceedings of a meeting or conference. A copyright fee will apply if there is a charge to the user or if the materials arising are directly or indirectly commercially supported.

Reuse in another journal before final publication is prohibited. Permission for reuse of an article (whether in whole or in part) in another publication is restricted to the final published version of the article. If an article is currently published on the APS “publish ahead of print” website (Articles in Press), then the author must wait to request permission to reuse the article, or any part of the article, until such time when the article appears in final-published form on the APS journal website.

Revised 2 May 2011.
Authors who do not have access to a subscription and who are not members of the APS may:
- purchase the article through the pay-per-view option, or
- purchase a Toll-Free Link from APS, which will allow them to post a link to the APS journals website (directly to the article) enabling unlimited free downloads for any user accessing the article via this Toll-Free Link.

Organizations Requesting Permission to Reuse the Work of Others for Educational Purposes

APS grants permission for free use of our articles (whether in whole or in part) in educational materials provided:
- there is no charge or fee for those materials, and/or
- those materials are not directly or indirectly commercially supported.
If a fee is charged or the materials are commercially supported, a fee will be assessed when permission is granted.

Translation of a Figure or Table into another Language

Figures and tables (as well as relevant text legends) may be translated into another language, for reuse. Full citation and attribution for the English original is required, as well as a disclaimer regarding the completeness and accuracy of the translation. Full article translations may require a licensing contract.

APS Policy on Funding Agencies

Authors whose funding agencies, such as the NIH, require posting of their published article in PubMedCentral (PMC) are covered by the APS funding agency policy (see http://www.the-aps.org/publications/journals/nihpolicy.htm). To assist our authors who acknowledge funding from these agencies, APS submits the final published article to PMC on their behalf. Articles by authors who pay the AuthorChoice open access fee ($2000 for research articles and $3000 for review articles) will be made publicly available when the final version is published on the APS journal website. APS will deliver the AuthorChoice article to PMC for posting by them. For details, see http://www.authorchoice.org.

Cost of Publication

Mandatory Submission Fee

There is a one-time Mandatory Submission Fee of $50 for each article submitted to most of the APS Journals. This fee is nonrefundable. The page charges are waived for authors of reviews, editorials, and letters and for those publishing in Physiological Reviews, Physiology, and Advances in Physiology Education.

Page charges

To recover part of publication costs, the APS charges authors of research articles $70 per printed page. By signing the Mandatory Submission Form, the author agrees to pay page charges once his/her paper is published. Excessive changes made in proof may be subject to additional charges.

Forms customized to your manuscript will become available on completion of the submission process; check the Home Page of the journal you are submitting to for blank forms.

Cost of color

We will publish scientifically necessary color figures free of charge if the first or the last author is an APS member in good standing (this includes student members). Please submit in color only if you intend for the figure(s) to be published in color. Unnecessary color figures are not permitted in the Journals, and in such cases authors will be required to provide a black and white version suitable for printing. The APS Publications Department is the final arbiter of whether color for a figure is scientifically necessary. Nonmembers will be charged the low subsidized rate of $400 per color figure. APS will not delay publication of any article for the sake of a pending membership application; membership status will be assessed at the time the color fee is due.

Color is free for authors publishing in Physiological Reviews and Physiology.

Reprint services

Please order reprints when you receive the proof of your article. The Reprint Order Form is enclosed in the electronic proof package. Please fill it out and send within two business days to the address indicated on the form.

If your article has color figures, there is an additional press charge of $100 per 100 reprints ordered.

Toll-free link: at your request, the APS can create a toll-free link from your online published article to a URL you specify. Readers accessing your article from this URL can do so without a subscription to the journal. The per-article cost is $150 ($250 for articles in Physiological Reviews) and can be noted on the Reprint Order Form. Payment for the link will be added to the invoice for publication fees.

AuthorChoice program for open access

You may now choose to pay a fee ($2000 for research articles, and $3000 for reviews) to make your online article free immediately (for more information on the APS AuthorChoice program, see http://www.authorchoice.org).

Restrictions on Prepublication

Except in reviews and editorials, the APS Journals will not accept submissions in which, other than in abstracts of less than 400 words, a significant portion of the data in the form of figures and/or tables has been published elsewhere. For the APS guidelines regarding duplicate and/or prior publication, and for exceptions pertaining to the Journal of Neurophysiology, which now receives for consideration manuscripts that have previously been posted to preprint servers, see the APS Ethical Policies and Procedures at http://www.the-aps.org/publications/authorinfo, which also appears at the end of this document.

Use of Previously Published Illustrations

APS Journals do not allow the use of previously published illustrations in research papers, regardless of modification or adaptation; research articles must contain original illustrations only. If scientifically appropriate, previously published illustrations may be included only in reviews, editorials, or letters, and only if permission is obtained from both the author and the original publisher. The authors are responsible for obtaining permission letters and must include them with their accepted manuscript in advance of publication. Authors are also responsible for providing publication-quality electronic files or laser prints of the previously published illustrations. These are best obtained from the original publisher or original author. Previously published images downloaded from the Internet are not acceptable for publication. See also the Special Considerations for Invited Authors at http://www.the-aps.org/publications/authorinfo.

Conflict of Interest

All funding sources supporting the work and all institutional or corporate affiliations must be disclosed in the manuscript. Authors are required at the time of submission to disclose to the APS Publications Office any potential conflict of interest, financial or otherwise (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, lack of access to data, or lack of control of the decision to publish, or any other potential conflict). Authors who have commercial associations must assert that they accept full responsibility for the conduct of the trial, had full access to all the data, and controlled the decision to publish. Any potential conflict of interest in connection with the submitted article must be disclosed in the Conflict of Interest Disclosure section of the Web-based manuscript submission process. Such information, unless already disclosed in the submitted article, will be held in confidence while the paper is under review. If the article is accepted for publication, information on the potential conflict of interest, or lack thereof, must be noted by the author in the manuscript file as a “Disclosures” statement following the Acknowledgments section of the paper.

Authorship Changes

After submission of the manuscript, if you realize that changes to authorship (e.g., altering the order of authorship or adding/removing a name) are needed, please follow these steps:
- Have ALL authors sign it.
- Fax or e-mail the signed form to the APS Peer Review office (301-634-7243).

“Submitted” and “Accepted” Dates

The “submitted” date for a manuscript is the date when the manuscript was submitted to the online Peer Review System. The “accepted” date is the date when the official letter of acceptance is sent out (usually via e-mail) from the Review Editor.

Use of Humans and/or Animals in Experiments

The research described in papers submitted to any of the APS publications that involves the use of human beings, including healthy volunteers, must adhere to the principles of the Declaration of Helsinki (see http://www.wma.net/en/30publications/10policies/b3/index.html), as well as in Title 45, US Code of Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 2001, effective December 13, 2001 (see http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm). Research involving animals must adhere to APS’s Guiding Principles in the Care and Use of Vertebrate Animals in Research and
APS insists that all investigations involving humans or animals reported in its publications be conducted in conformity with these principles, and that a statement of protocol approval from an IRB or IACUC or equivalent is included in the methods section of the paper. In describing surgical procedures, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed. Manuscripts reporting the results of experiments on human subjects, including healthy volunteers, must include a statement that informed consent was obtained. Editors/Associate Editors are expected to refuse papers in which evidence of the adherence to these principles is not apparent. They reserve the right to judge the appropriateness of the use of animals and humans in experiments published in the journals. Differences of opinion will be adjudicated by the Publications Committee.

Registering of clinical trials is a requirement for peer review and publication for any study that uses clinical trials. There must be a statement in the Methods section that states where the clinical trial was registered (for example, see the registration site sponsored by the United States National Library of Medicine, at http://www.clinicaltrials.gov).

Fetal Tissue Research

The American Physiological Society Publications require all papers submitted to any of the APS Journals and involving the use of human fetuses, fetal tissue, embryos, and embryonic cells to adhere to the US Public Law 103-41, effective August 1991. Please read the APS Policy Regarding Publication of Research on Human Fetuses, Fetal Tissue, Embryos, and Embryonic Cells (see http://www.the-aps.org/publications/authorinfo) and the criteria that must be met by all researchers submitting their work to the APS Journals.

Data Repository Standards

All authors of articles submitted to APS Journals should submit their relevant data to all appropriate data repositories, such as the National Center for Biotechnology Information (NCBI) and the European Bioinformatics Institute (EBI).

MIAME Standard for Microarray Data

The APS has adopted the microarray data standard developed by the Microarray Gene Expression Data society (MGED; http://www.mged.org) and requests that all authors using microarray data analysis in their research submit a complete data set to one of three databases prior to manuscript submission: the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo); the EMBL-EBI ArrayExpress repository (http://www.ebi.ac.uk/arrayexpress); or the Center for Information Biology Gene Expression (CIBEX) database (http://cibex.nig.ac.jp/index.jsp). Also, provide the set of login credentials (user name and password) that will let referees access the data set during review, if it is set up as a private resource.

HUGO Gene Nomenclature

In accordance with the HUGO Gene Nomenclature Committee (HGNC), the APS requests that authors obtain approval for new human gene symbols by contacting HGNC at http://www.genenames.org. For mouse genes, contact Mouse Genome Informatics (MGI) at http://www.informatics.jax.org. Additional information on gene nomenclature guidelines is available from the HGNC and the MGI websites.

Unique Materials and Data Banks

Work published in the APS Journals must necessarily be independently verifiable. Authors describing results derived from the use of antibodies, recombinant plasmids and cloned DNAs, mutant cell lines or viruses, and other similarly unique materials are expected to make such materials available to qualified investigators on request. Authors should also submit published nucleic acid/amino acid sequences to a widely accessible data bank. Sequence data for the United Protein Database (UniProt) should be submitted directly to UniProt using SPIN, a new web-based tool for submitting protein sequences (see http://www.uniprot.org/). Also, for other special types of submissions (e.g., genomes, bulk submissions), additional submission protocols are available from the following organizations:

- **DDBJ**: DNA Data Bank of Japan
  http://www.ddbj.nig.ac.jp/
- **EMBL**: EMBL Nucleotide Sequence Database
  http://www.ebi.ac.uk/embl
- **GenBank**: National Center for Biotechnology Information
  info@ncbi.nlm.nih.gov or http://www.ncbi.nlm.nih.gov/genbank

See also MIAME Standard for Microarray Data (above) and Data Supplements (below).

Formatting Requirements

File Formats for Online Submission and Print

Please submit a Microsoft Word (.doc) file or a Rich Text Format (.rtf) file to the APS Peer Review System. Separate files must be submitted for all discrete elements of the manuscript, e.g., separate files for each figure and table, and a separate file for the complete text of the manuscript. The manuscript file should include the abstract, all main text, references, figure legends and table legends, etc.

Organization of the Manuscript

APS accepts manuscripts in one of two formats: double-spaced in wide, one-column traditional manuscript format, or single-spaced in two-column journal format. If you choose two-column format and wish to embed copies of the figures into the text for review purposes, you may, but you must also include separate figure files for production. Additionally, if you do choose to embed figures, any revisions to figures during review will require you to load the newly revised individual figure files to the APS Peer Review System, and the copies embedded into the text must also be updated to reflect the revised figures (see sections on Figures, below).

Arrange as follows (each of these bulleted items should begin on a new page):

- title page
- abstract and keywords
- main text (introduction; Materials and Methods, or Experimental Procedures; Results; Discussion, with conclusions)
- text footnotes
- acknowledgments
- references
- figure legends
- tables

Be sure the text is clear and concise, conforming to accepted standards of American English style and usage. Avoid jargon, clichés, and laboratory slang. Authors for whom English is not their native language are strongly encouraged to seek the aid of a professional English language editorial service. See Manuscript Sections, below, for further description.

Abbreviations, Symbols, and Terminology

All abbreviations should be explicitly defined at first usage. However, internationally accepted abbreviations do not need to be defined. Please consult the list of accepted abbreviations for our journals (http://www.the-aps.org/publications/journals/abbrv.pdf). For word usage, symbols, etc., authors are referred to Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers (6th ed., 1994). For chemical and bio-chemical terms and abbreviations, consult the recommendations of the IUPAC-IUB Combined Commission on Biochemical Nomenclature. Online resources can be found at http://www.iupac.org. Isotope specification must conform to the IUPAC system. Authors are referred to the following articles for style in specialized fields: “Glossary on respiration and gas exchange” (J Appl Physiol 34: 549–558, 1973); and “Glossary of terms for thermal physiology” (J Appl Physiol 35: 941–961, 1973).

Special Symbols

For special characters not available on the standard 104-key keyboard (e.g., Greek characters, mathematical symbols, figure symbols), use the “Insert Symbol” function in Microsoft Word; do not use math font or image files (e.g., GIF) within the text for special characters or text constructions.
Spelling and Editorial Style

Authors should follow Webster’s Third New International Dictionary or Merriam-Webster’s Collegiate Dictionary, 11th edition, for spelling and compounding. The APS Journals use American English rules for spelling. All manuscripts will be edited by highly trained professional copy editors, according to the APS house style and guidelines.

Trade Names

Proprietary (trademarked) names should be capitalized, with the spelling carefully checked. The generic name or generic descriptor should accompany the trade name the first time it appears.

Genes and Proteins

When reporting studies on genes and proteins, be sure to follow the established style conventions of the genetics community for properly expressing gene vs. protein symbols and names.

Cell Lines and Reagents

The source of cells utilized (species, sex, strain, race, age of donor, whether primary or established) should be clearly indicated. The source of reagents should be stated (name, city, and state within parentheses) when first cited. If tests to rule out the presence of mycoplasmal contamination were not performed, this fact should be clearly stated. Other data relating to unique biological, biochemical, and/or immunological markers should also be included if available, with their source identified.

Publication of results is based on the principle that results must be independently verifiable. Authors are expected to make unique reagents available to qualified investigators either directly or through a recognized distributor. See also Unique Materials and Data Banks (above) and Ethical Policies and Procedures (appearing at the end of this document) for other requirements.

Manuscript Sections

Title Page

All submissions must contain a title page. The title page must contain the full title of the article; author(s) name(s); all departments and institutions in which the work was done; an abbreviated title for the running head; and the corresponding author’s name, e-mail address, and physical address for correspondence. Only one author may be designated as the corresponding author.

Title

Make the title informative. Avoid unnecessary words like “Studies in . . . .” The title must not exceed 160 characters, including spaces between words.

Authors

List all authors’ names and their first names or initials exactly as they should be known, in the order of importance of their contribution to the study. Do not include any specific titles (e.g., PhD, MD, and Prof. are not needed). “Group authorship” is allowed, with the name of a group (such as a consortium or program) to be listed as an author, with members of the group listed in the Acknowledgments section; however, the Program Director of the named group must be the one who signs for the group when the group’s “author” signature is needed, i.e., on a Mandatory Submission Form or a Change of Authorship Form.

Authors who publish in APS Journals may now present their names in non-Latin characters (in their native writing system) alongside the standard English transliteration of their name in the main author line of the published article; for example, “Ta-Ming Wang (±A49†).” We will accept any non-Latin languages that have standard Unicode characters (http://www.unicode.org) designated for the native characters. For authors who choose this option, please only provide the native expression for the original written form of the transliterated name; that is, do not include any associated degree, rank, or title information in the native format. This feature is meant for the person’s name only, not for ancillary information regarding academic achievement or institutional affiliation. To take advantage of this new feature, please insert the native expression of your name alongside the standard English transliteration in the main title page of your manuscript submission.

Affiliation

List all departments and institutions in which the work was done, with city and state or country. Identify each author’s affiliation by superscript numbers matched to the appropriate institution. Affiliation must reflect the organization(s) supporting the author(s) while the work was done. This may differ from the current affiliations of the author(s), which will be listed in such cases in the Acknowledgments section as the present addresses of the authors.

Running head

The running head is an abbreviated version of the title, which will appear at the top of every page subsequent to the first page. Running heads must not exceed 60 characters including spaces between words.

Contact information

Only one author may be designated as the corresponding author. A full address for correspondence will be published and must be included, with a current, valid e-mail address for the corresponding author. The address of the sole corresponding author (there must be only one corresponding author) will appear on the first page of the article, if the article is accepted for publication. Please note that a valid e-mail address is essential to participate in the APS electronic proofing service. Also, provide phone and fax numbers for use while your article is in production. If the contact information to be used during production differs from that to be included in the final article, indicate this explicitly. To contact APS during the submission and peer review and/or during production after acceptance, go to the APS website (http://www.the-aps.org) and choose the appropriate journal’s web page.

Abstract

An informative one-paragraph abstract of not more than 250 words must accompany each manuscript. It must state concisely what was done and why (including species and state of anesthesia), what was found (in terms of data, if space allows), and what was concluded.

Keywords

Include three to five words or short phrases, relevant to the article, that do not appear in the title or running head.

Introduction

Provide a brief overview of the scope and relevance of the study, especially with regard to previous advancements in related fields.

Materials and Methods

Describe techniques, cell/animal models used, and lists of reagents, chemicals, and equipment, as well as the names of manufacturers and suppliers, including URLs for those supplies obtained online, so that your study can be most easily replicated by others. Also in this section, describe the statistical methods that were used to evaluate the data. If clinical trials were used, a statement of registration is required; also, for all investigations involving humans or animals, a statement of protocol approval or an IRB or IACUC, or an equivalent statement, must be included. All animal or human studies must contain an explicit statement that the protocols were submitted to, and approved by, an institutional review board or committee or that the protocols were performed under a license obtained from such a committee, board, or governing office. (see Use of Humans and/or Animals in Experiments above). See Abbreviations, Symbols, and Terminology (above) for style information.

Results

Provide the experimental data and results as well as the particular statistical significance of the data. APS has published an editorial on the use of statistics (http://physiolgenomics.physiology.org/cgi/content/full/18/3/249), and authors are encouraged to consult it.

Discussion

(Sometimes combined with the results in a section called “Results and Discussion”). Explain your interpretation of the data, especially compared with previously published material cited in the References.

Acknowledgments

The Acknowledgments section is where you may thank people indirectly involved with the research (e.g., technical assistance, gifts of samples, reagents, or cell lines, loans of equipment or laboratory space, comments or suggestions during the creation of the manuscript). However, it is important that anyone listed here know in advance of your acknowledgment of their contribution, as documented during the submission process. Current addresses of authors (which may differ from those in the affiliation line) may be included here.

Do not include “promissory notes.” APS Journal policy is against inclusion of implicit or explicit promises that future work will be published.

Do not include dedications (e.g., to persons living or deceased); Dedications of articles are not permitted.
Grants

List the grants, fellowships, and donations that funded (partially or completely) the research. However, industry-sponsored grants should be listed under Disclosures.

Disclosures

Authors are required at the time of submission to disclose to the APS Publications Office any potential conflict of interest, financial or otherwise. See the Conflict of Interest description above, or see the complete details of the APS Ethical Policies at http://www.the-aps.org/publications/authorinfo, which also appears at the end of this document. If the article is accepted for publication, information on the potential conflict of interest, or lack thereof, must be noted by the author in the manuscript file as a “Disclosures” statement following the Acknowledgments section of the paper.

Citing Unpublished Observations, Personal Communications and In Press Manuscripts

Submitted papers still in preparation or in peer review and/or any other unpublished materials, observations, or personal communications cannot be included in the reference list, which may only list published work. However, such material can be cited in the text, but at submission, authors will be required to confirm that all individuals acknowledged in the manuscript are aware that they are being acknowledged and approve of the manner and the context of the acknowledgement. This includes, but is not limited to the following circumstances:

- to publish information disclosed in a personal communication or unpublished observation
- to recognize additional individuals who helped in preparation of the manuscript
- for permission from a copyright holder to discuss information that is “in press” and not yet available, online or otherwise.

Reference List

Authors are responsible for accuracy of citations. References must be limited to directly pertinent published works or papers that have been accepted for publication. An abstract, properly identified as “Abstract”, may be cited only when it is the sole source.

Reference lists should be arranged alphabetically by author and numbered serially. The reference number should be placed in parentheses at the appropriate place in the text.

The examples given below are shown with numbers because that is the style for most APS Journals.

For an exhaustive set of examples for properly citing various types of publications, including articles published on the web, technical documents, congress proceedings, articles with errata/corrigenda, translations, and articles with large groups of authors, go to http://www.the-aps.org/publications/authorinfo/examplerefs.htm.

The style of citation should be as follows, with journal name abbreviated as in Medline, PubMed, and Index Medicus. Appropriate templates for your citation management software are available from the respective company web sites.

Examples

Journal Articles


Book References


APS Handbook of Physiology Series


DOI's and Early Publication in Articles in Press

These articles may be cited and establish publication’s priority before they appear in final print and online forms. (Please note the required use of a “digital object identifier”—DOI—in this citation.)


Note for reference lists in the Journal of Neurophysiology

Reference lists for the Journal of Neurophysiology should be arranged alphabetically by author. For in text citations, appropriate author name and year for each reference should be included in parentheses at the proper point in the text using the following style:

• One author (Brown 1982).
• Two authors (Brown and Smith 1982).
• Three or more authors (Brown et al. 1982).

If more than two references are cited by different authors, separate entries with a semicolon (Brown 1982; Smith 1983). If more than two references are cited by the same first author (or single author), use “et al.” where appropriate plus the date, even if the subsequent authors are not the same in all the references (Brown et al. 1982, 1983). Note the use of commas between two consecutive years or nonconsecutive years and do NOT use dashes for ranges (Brown et al. 1982, 1983, 1986, 1987, 1988, 1989). If more than two references with the same year and author(s) are cited, use lowercase letters after the year (Brown 1982a, 1982b). Lowercase letters should be inserted in the same-year references in the reference list.

Footnotes

Text footnotes should be numbered consecutively throughout. These should be assembled on a separate page as endnotes.

Types of Articles

The APS Journals publish a variety of article types in addition to the regular research papers. For descriptions of the types of articles published in a particular journal, go to that journal’s page at the APS website (http://www.the-aps.org).

Figures

APS uses digital publishing methods throughout the journal production process. Your article will be published both in the print journal and online.

We have several specific requirements for digital graphics formats to ensure the best possible reproduction in both media.

Computer screens, laser printers, and offset presses are significantly different devices. The ability to print your graphics well on a desktop laser printer does not mean the image is suitable for composition and production of your article in final form. A detailed set of guidelines is available from APS to help you prepare image files that will provide high-quality reproductions in the APS Journals, both in print and online.

Authors may be asked to prepare new figures if those submitted are not suitable for publication; this will most likely delay publication of the paper.

Always prepare original graphics at print publication-quality resolution. If your manuscript is accepted for publication, APS will require the high-resolution files for print output.

Use applications capable of creating high-resolution PDF files.

Figures should be generated at the size they are to appear in the journal (printed 1:1).

For complete guidelines, go to http://www.the-aps.org/publications/authorinfo/figures/index.htm. These guidelines include important descriptions of inappropriate figure manipulation (and how to avoid these presentation errors), as well as what constitutes unethical manipulation of figures. Fabricating a report of research or suppressing or altering data to agree with one’s conclusions is considered fraud. This includes altering figures in such a way to obscure, move, remove, or introduce information or features.

Use of Animals or People in Photographs

• Photographs of animals or people may be published when scientifically necessary to illustrate a setup or convey the findings of the paper. For a photograph of a person, a signed letter of consent is required from the person or their legal agent or guardian.
• When a diagram is preferable to illustrate a setup, if it is not possible to obtain a drawing, the author should describe the setup in the methods section of the paper.
• Photographs to convey findings may be published when the data are conveyed in the image as in developmental biology or genetic modifications where such photographs are standard practice.
• With respect to other areas, the decision whether to publish a
photograph will be based upon the editor’s determination whether the photograph is scientifically necessary.

- The journals should avoid publishing photographs that might be perceived as raising animal welfare concerns. For example, it is preferable to show only the relevant portion of the animal, and photographs should not show blood or people handling the animals except close-ups where only gloved hands are seen.

Tables

Whenever possible, authors are encouraged to submit figures rather than tables. Statistical summary tables should be submitted when possible, rather than tables with many lines of individual values. Lengthy tables of data that cannot be presented in a suitable manner, according to APS standards for print publication, may be extracted and set as a supplement to the online article. These supplements remain an integral part of the article for the reader, and links directly to the supplements will be embedded and prominently indicated at all points of entry to the online article (see Data Supplements, below).

Submitted tables should adhere to the following guidelines:

- Tables must not duplicate material in text or figures.
- Tables should be numbered consecutively with Arabic numerals and prepared with the size of the journal page in mind: 3.5 in. wide, single column; 7 in. wide, double column.
- Each table should have a brief title; explanatory notes should be in the legend, not in the title.
- Nonsignificant decimal places in tabular data should be omitted.
- Short or abbreviated column heads should be used and explained if necessary in the legend.
- Statistical measures of variations, SD, SE, etc., must be identified. (Example: “Values are means ± SE.”)
- Table footnotes should be listed in order of their appearance and identified by standard symbols: *, †, ‡, § for four or fewer; for five or more, consecutive superior lowercase letters should be used.

Mathematical Equations and Modeling

Mathematical aspects of articles normally should be addressed to the many readers of the Journal who are not mathematicians. The presentation should include the mathematical strategy, the assumptions on which the mathematics are based, and a summary of the meaning of the final mathematical statement and its limitations.

Equations

Mathematical equations should be simplified as much as possible and carefully checked. Use the slant line (/) for simple fractions \((a + b)/(x + y)\) in the text rather than the built-up fraction

\[
\frac{a + b}{x + y}
\]

which should only be used if the equation is offset from the text as in this example.

Use subscripts or superscripts wherever feasible and appropriate, to simplify the equations.

Please use notation that is consistent with the standard nomenclature in applied mathematics. As an aid to the reader, please state the convention that you are following, especially if it is uncommon.

Symbols should be defined as they first appear in the text, and a Glossary may be included (and helpful) in articles with many different symbols, specifying the units (dimensions) as well as each definition. The Glossary will usually precede the Methods section.

APS style allows punctuation in displayed equations.

Mathematical Models

Presentation of the model(s) must be sufficiently clear to allow physiologists with limited experience in modeling to follow the model development, limitations, and physiological relevance. Assumptions concerning the importance of physiological processes included in the model should be clearly stated. If the model equation(s) require solution, the method of solution should be described in sufficient detail to permit readers to duplicate the solution in their own laboratories. Algorithms from commercial software libraries should be so identified. Details of the solution strategy may be summarized in an Appendix (for an example, see http://jap.physiology.org/cgi/reprint/96/1/65.pdf).

For simulations, sources or estimation methods for all parameter values should be presented and the numerical values given in the text or a table. A sensitivity analysis must be performed for important parameters (covering ranges of values relevant to the manuscript) to determine how the model predictions are affected by numerical parameter values.

If the model is used to estimate parameter values, measures of the uncertainties associated with these estimates should be presented.

For models intended for use in a predictive setting, validation of the model with a data set not used for model parameter estimation (i.e., cross-validation) is recommended. Sensitivity analysis or parameter uncertainty determination is an important component of modern modeling practice that allows assessment of the validity of a model.

Results obtained with the model(s) should be compared with appropriate physiological data, either from literature or from new experiments. Simulation results may be examined for prediction of changes or trends in physiological variables similar to those reported for in vitro or in vivo studies. The discussion should include information on the physiological significance of the model study, limitations of the model, and suggestions for new modeling and/or experimental studies.

Data Supplements

Video files, extensive tables of data, and other supplemental material that cannot be feasibly published in the printed journal may be submitted for inclusion in the online journal (without charge to the author). Such material must be submitted for peer review along with the finished manuscript and must meet the approval of the journal Editor. Questions regarding data supplements may be directed to the Online Production Editor (mgenrety@the-aps.org). For microarray data deposits, see above (MIAME Standard for Microarray Data).

Long Data Tables

Long data tables should be submitted in Microsoft Excel or in Microsoft Word table format. Each table should include a title explaining what the table shows. Tables published online may look different from how they were originally submitted due to the limits of the HTML format.

Ethical Policies and Procedures

Authorship. The Editors of the journals of the American Physiological Society (APS) expect each author to have made an important scientific contribution to the study and to be thoroughly familiar with the original data. The Editors also expect each author to have read the complete manuscript and to take responsibility for the content and completeness of the manuscript and to understand that if the paper, or part of the paper, is found to be faulty or fraudulent, that he/she shares responsibility with his/her coauthors. The Mandatory Submission Form should be signed by each author. In cases in which obtaining a signature from each author would delay publication, the corresponding author’s signature is sufficient provided that the corresponding author understands that he or she signs on behalf of the other authors who have not signed the form. An author’s name can be removed only at his/her request, but all coauthors must sign a change of authorship agreement for any change in authorship (additions, removals, or change of order) to be made.

Author Conflict of Interest. All funding sources supporting the work and all institutional or corporate affiliations must be disclosed in the manuscript.
Authors of research articles are required at the time of submission to disclose to the APS Publications Office any potential conflict of interest, financial or otherwise (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, lack of access to data, or lack of control of the decision to publish, or any other potential conflict). Authors who have commercial associations must assert that they accept full responsibility for the conduct of the trial, had full access to all the data, and controlled the decision to publish. Any potential conflict of interest in connection with the submitted article must be disclosed in the Conflict of Interest Disclosure section of the Web-based manuscript submission systems. Links to the submission system can be found on any APS journal home page. Such information, unless already disclosed in the submitted article, will be held in confidence while the paper is under review. If the article is accepted for publication, information on the potential conflict of interest, or lack thereof, must be noted by the author in the manuscript file as a “Disclosures” statement following the Acknowledgments section of the paper.

Editor and Reviewer Conflict of Interest. Editors and Reviewers should avoid making decisions on papers for which they may have a potential conflict of interest, financial or otherwise. Reviewers who are collaborating with the author, or who are working on very similar research, should recuse themselves from reviewing a paper for which they have a conflict. An Editor in Chief should have a Consulting Editor or Associate Editor make a decision on a paper for which he or she has a conflict. When an Editor in Chief submits a paper to his or her journal, the paper is automatically assigned to a Guest Editor, a Consulting Editor, or an Associate Editor, who will handle all aspects of the peer review of the paper. Such reviews are handled in the web-based peer review system in such a way that the author (i.e., the Editor in Chief) will not have access.

Duplicate Publication, Plagiarism, Falsification. The journals of the APS accept only original work. Using manuscripts that are original work, no part of which has been submitted for publication elsewhere except as brief abstracts. When submitting a paper, the corresponding author should include copies of related manuscripts submitted or in press elsewhere. Taking material from another’s work and submitting it as one’s own is considered plagiarism. Taking material (including tables, figures, and data; or extended text passages) from the author’s own prior publications is considered redundant publication or self-plagiarism.

The prohibition against duplicate publication includes data from control experiments. Repetition of control experiments is scientifically warranted when the methodology and/or conditions have changed, even to a minimal degree. However, when the methodology and conditions are identical, repetition of control experiments in animal subjects may violate U.S. Animal Welfare Act and Public Health Service Policy requirements as well as standards in other countries, for use of the minimum number of animals needed to accomplish the science. In this case only, reuse of control data will not be considered duplicate publication. Fabricating a report of research or suppressing or altering data to agree with one’s conclusions is considered fraud; this includes altering figures in such a way as to obscure, move, remove, or introduce information or features. Examples of fraudulent/inauspicious alteration of figures include, but are not limited to, splicing and reassembling noncontiguous lanes of gels without separation by white space or lines and altering the background such that information is lost.

Prior Publication. Material published by the author before submission in the following categories is considered prior publication: 1) articles published in any publication, even online-only, non-peer reviewed publications, such as Nature Precedings or the physics arXiv (see exception below for the Journal of Neurophysiology); 2) articles, book chapters, and long abstracts containing original data in figures and tables, especially in proceedings publications; as well as posters containing original data disseminated beyond meeting attendees, e.g., displayed in websites such as that maintained by F1000; 3) widely circulated, copyrighted, or archival reports, such as the technical reports of IBM, the preliminary reports of MIT, the institute reports of the US Army, or the internal reports of NASA.

Doctoral dissertations that are made available by UMI/Proquest or institutional repositories are not considered prior publication. Data portions of submitted papers that have appeared on web site will be permitted, with the proviso that the author inform the Editor at the time of the submission that such material exists so that the Editor can determine the suitability of such material for publication. Failure to do so will result in an automatic rejection of the manuscript. Examples of such work include, but are not limited to, immunofluorescence micrographs and/or animated gif/video files posted on a web site, or NIH-mandated posting of DNA microarray data. After the article is published in an APS journal, the data should be removed from the author’s web site.

Authors with concerns about possible prior publication that does not fall clearly into one of these categories should contact the Director of Publications and forward the material for examination.

Authors submitting to the Journal of Neurophysiology (JN) may submit papers that have been previously posted to preprint servers and other non-peer-reviewed websites. Once you have submitted your manuscript to JN, we ask that you not subsequently post this manuscript, or a revised version of it, to a preprint server. However, if you recognize that you have a final reject decision at JN or if you withdraw it from editorial consideration at JN, this restriction is then lifted. Authors submitting manuscripts to preprint servers must be sure to retain the copyright to their work, which can then be transferred to the publisher when a later version of the work is accepted at a traditional peer-reviewed journal (this is standard at arXiv and Nature Precedings). Questions about whether a particular preprint server venue is allowed under this rule should be addressed to the JN Editor in Chief, David Linden at dlinden@jhu.edu. Authors will be asked at submission to disclose whether their manuscript has been posted to a preprint server, to identify the preprint server, and to provide a file of the most recent version of the posting and the DOI or a working link to it. This is a trial exception to APS policy that applies to submissions to the Journal of Neurophysiology through March, 2013 and subject to change thereafter.

Experiments Involving Animals or Humans. Authors using humans, animals, or fetal tissue in their experiments should refer to the APS policies on those subjects: Guiding Principles for Research Involving Animals and Human Beings; and the Policy on the Publication of Research on Human Fetuses, Fetal Tissue, Embryos, and Embryonic Cells.

Ethical Procedure. APS reviewers have a responsibility to report suspected duplicate publication, fraud, plagiarism, or concerns about animal or self-plagiarism to the Editor. However, if you recognize that you have a report that he/she is refereeing, or has recently refereed, a similar or identical paper for another journal by the same author(s). Readers may report that they have seen the same article elsewhere, or authors may see their own published work being plagiarized. In all cases we address ethical concerns diligently following an issue-specific standard practice as summarized below. The first action of the Journal Editor is to inform the Publications Committee Chair through the Director of Publications by supplying copies of 1) the relevant material and 2) a draft letter to the corresponding author asking for an explanation in a nonjudgmental manner. The Publications Committee Chair must approve any correspondence before it is sent to the author. If the author’s explanation is unacceptable and it seems that serious unethical conduct has taken place, the matter is referred to the Publications Committee. After deliberation, a decision is made whether the case is sufficiently serious to warrant a ban on future submissions to, and on serving as a reviewer for, APS journals and/or if the offending author’s institution should be informed. The decision has to be approved by the Executive Cabinet of the APS Council, and the author has the right to appeal a sanction, with the opportunity to present his/her position to the Publications Committee and the full APS Council.

If the infraction is less severe, the Editor, upon the advice of the Publications Chair, sends the author a letter of reprimand and reminds the author of APS publication policies; if the manuscript has been published, the Editor may require the author to publish an apology in the journal to correct the record. If, through the author’s actions, APS has violated the copyright of another journal, the Publications Chair writes a letter of apology to the other journal.

In serious cases of fraud that result in retraction of the article, a retraction notice will be published in the journal and will be linked to the article in the online version. The online version will also be marked “retracted” with the retraction date.

Updated Spring 2011.
GUIDING PRINCIPLES FOR RESEARCH INVOLVING ANIMALS AND HUMAN BEINGS

The research described in papers submitted to any of the APS publications that involve the use of human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 2001, effective December 13, 2001 (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm). Research involving animals must adhere to APS’s Guiding Principles for the Care and Use of Vertebrate Animals in Research and Training. APS insists that all investigations involving humans or animals reported in its publications be conducted in conformity with these principles and that a statement of protocol approval from an IRB or IACUC or equivalent is included in the methods section of the paper. In describing surgical procedures, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these are used, evidence must be provided that anesthesia of suitable grade and duration was employed. Editors/Associate Editors are expected to refuse papers in which evidence of the adherence to these principles is not apparent. They reserve the right to judge the appropriateness of the use of animals and humans in experiments published in the journals. Differences of opinion will be adjudicated by the Publications Committee.

WORLD MEDICAL ASSOCIATION
DECLARATION OF HELSINKI

Ethical Principles for Medical Research Involving Human Subjects1

A. Introduction

1. The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Medical research involving human subjects includes research on identifiable human material or identifiable data.

2. It is the duty of the physician to promote and safeguard the health of the people. The physician’s knowledge and conscience are dedicated to the fulfillment of this duty.

3. The Declaration of Geneva of the World Medical Association binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act only in the patient’s interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient.”

4. Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

5. In medical research on human subjects, considerations related to the well-being of the human subject should take precedence over the interests of science and society.

6. The primary purpose of medical research involving human subjects is to improve prophylactic, diagnostic and therapeutic procedures and the understanding of the aetiology and pathogenesis of disease. Even the best proven prophylactic, diagnostic, and therapeutic methods must continuously be challenged through research for their effectiveness, efficiency, accessibility and quality.

7. In current medical practice and in medical research, most prophylactic, diagnostic and therapeutic procedures involve risks and burdens.


8. Medical research is subject to ethical standards that promote respect for all human beings and protect their health and rights. Some research populations are vulnerable and need special protection. The particular needs of the economically and medically disadvantaged must be recognized. Special attention is also required for those who cannot give or refuse consent for themselves, for those who may be subject to giving consent under duress, for those who will not benefit personally from the research and for those for whom the research is combined with care.

9. Research Investigators should be aware of the ethical, legal and regulatory requirements for research on human subjects in their own countries as well as applicable international requirements. No national ethical, legal or regulatory requirement should be allowed to reduce or eliminate any of the protections for human subjects set forth in this Declaration.

B. Basic Principles for All Medical Research

10. It is the duty of the physician in medical research to protect the life, health, privacy, and dignity of the human subject.

11. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and on adequate laboratory and, where appropriate, animal experimentation.

12. Appropriate caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

13. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol. This protocol should be submitted for consideration, comment, guidance, and where appropriate, approval to a specially appointed ethical review committee, which must be independent of the investigator, the sponsor or any other kind of undue influence. This independent committee should be in conformity with the laws and regulations of the country in which the research experiment is performed. The committee has the right to monitor ongoing trials. The researcher has the obligation to provide monitoring information to the committee, especially any serious adverse events. The researcher should also submit to the committee, for review, information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest and incentives for subjects.

14. The research protocol should always contain a statement of the ethical considerations involved and should indicate that there is compliance with the principles enunciated in this Declaration.

15. Medical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given consent.

16. Every medical research project involving human subjects should be preceded by careful assessment of predictable risks and burdens in compar-
ison with foreseeable benefits to the subject or to others. This does not preclude the participation of healthy volunteers in medical research. The design of all studies should be publicly available.

17. Physicians should abstain from engaging in research projects involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians should cease any investigation if the risks are found to outweigh the potential benefits or if there is conclusive proof of positive and beneficial results.

18. Medical research involving human subjects should only be conducted if the importance of the objective outweighs the inherent risks and burdens to the subject. This is especially important when the human subjects are healthy volunteers.

19. Medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research.

20. The subjects must be volunteers and informed participants in the research project.

21. The right of research subjects to safeguard their integrity must always be respected. Every precaution should be taken to respect the privacy of the subject, the confidentiality of the patient’s information and to minimize the impact of the study on the subject’s physical and mental integrity and on the personality of the subject.

22. In any research on human beings, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail. The subject should be informed of the right to abstain from participation in the study or to withdraw consent to participate at any time without reprisal. After ensuring that the subject has understood the information, the physician should then obtain the subject’s freely-given informed consent, preferably in writing. If the consent cannot be obtained in writing, the non-written consent must be formally documented and witnessed.

23. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship with the physician or may consent under duress. In that case the informed consent should be obtained by a well-informed physician who is not engaged in the investigation and who is completely independent of this relationship.

24. For a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally authorized representative in accordance with applicable law. These groups should not be included in research unless the research is necessary to promote the health of the population represented and this research cannot instead be performed on legally competent persons.

25. When a subject deemed legally incompetent, such as a minor child, is able to give assent to decisions about participation in research, the investigator must obtain that assent in addition to the consent of the legally authorized representative.

26. Research on individuals from whom it is not possible to obtain consent, including proxy or advance consent, should be done only if the physical/mental condition prevents obtaining informed consent is a necessary characteristic of the research population. The specific reasons for involving research subjects with a condition that renders them unable to give informed consent should be stated in the experimental protocol for consideration and approval of the review committee. The protocol should state that consent to remain in the research should be obtained as soon as possible from the individual or a legally authorized surrogate.

27. Both authors and publishers have ethical obligations. In publication of the results of research, the investigators are obliged to preserve the accuracy of the results. Negative as well as positive results should be published or otherwise publicly available. Sources of funding, institutional affiliations and any possible conflicts of interest should be declared in the publication. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

C. Additional Principles for Medical Research Combined with Medical Care

28. The physician may combine medical research with medical care, only to the extent that the research is justified by its potential prophylactic, diagnostic or therapeutic value. When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects.

29. The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic method exists. Note of clarification on paragraph 29 of the WMA Declaration of Helsinki: The WMA hereby reaffirms its position that extreme care must be taken in making use of a placebo-controlled trial and that in general this methodology should only be used in the absence of existing proven therapy. However, a placebo-controlled trial may be ethically acceptable, even if proven therapy is available, under the following circumstances: Where for compelling and scientifically sound methodological reasons its use is necessary to determine the efficacy or safety of a prophylactic, diagnostic or therapeutic method; or Where a prophylactic, diagnostic or therapeutic method is being investigated for a minor condition and the patients who receive placebo will not be subject to any additional risk of serious or irreversible harm. All other provisions of the Declaration of Helsinki must be adhered to, especially the need for appropriate ethical and scientific review.

30. At the conclusion of the study, every patient entered into the study should be assured of access to the best proven prophylactic, diagnostic and therapeutic methods identified by the study. Note of clarification on paragraph 30 of the WMA Declaration of Helsinki: The WMA hereby reaffirms its position that it is necessary during the study planning process to identify post-trial access by study participants to prophylactic, diagnostic and therapeutic procedures identified as beneficial in the study or access to other appropriate care. Post-trial access arrangements or other care must be described in the study protocol so the ethical review committee may consider such arrangements during its review.

31. The physician should fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study must never interfere with the patient-physician relationship.

32. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician’s judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.

APS GUIDING PRINCIPLES FOR THE CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH AND TRAINING

As noted in the U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training,3 “Procedures involving animals should be designed and performed with due consideration of their relevance to human or animal health, the advancement of knowledge, or the good of society.” The use of animals is also justified to provide scientific, veterinary, and medical training that is not possible through other mechanisms.

Investigators should consider the appropriateness of the experimental procedures, the species of animals used, and number of animals required. Prospective approval of procedures on animal subjects should be obtained from an institutional animal care and use committee (IACUC) or similar oversight body as required under the relevant regulatory authorities. This review should also consider whether the use of animals in a given protocol could be replaced by other experimental approaches such as in vitro studies or computer modeling.

Only animals that are lawfully acquired shall be used in research and teaching. The procurement, transport, maintenance, and use of animals must in all cases comply with federal, state and local laws and regulations. In the United States, animal research may be subject to the Animal Welfare Act, the Public Health Service Policy on Humane Care and Use of Laboratory Animals, or other guidelines established by funding agencies. The PHS Policy requires institutions to use the Guide for the Care and Use of Laboratory Animals4 to develop and implement an institutional animal care and use program.

Analogies and other techniques should be used to minimize discomfort and pain except when the intervention would compromise experimental goals. Appropriate anesthetics must be used to eliminate sensibility to pain.

2 The Guiding Principles for the Care and Use of Animals in Research and Teaching were adopted by the American Physiological Society in 1953. They are based upon humane care principles formulated by Walter B. Conn in 1909. The revision was approved by the APS Council on July 16, 2010.

3 URL: http://grants.nih.gov/grants/olaw/references/phspol.htm#USGovPrinciples

during all surgical procedures. Drugs that produce muscle paralysis are not anesthetics. They must never be used alone for surgical restraint, only when animals are under anesthesia.

If the study requires the death of an animal, humane endpoints should be identified, and an approved method of euthanasia stipulated in the American Veterinary Medical Association’s Guidelines on Euthanasia should be used. Death is acceptable as the endpoint of a study only where euthanasia would compromise scientific outcomes and an IACUC or similar oversight body has approved the exception.

Animals used in research and education must be housed, fed, and maintained in a manner appropriate for their species and their condition. They should also be given appropriate veterinary care.

Personnel who care for or perform procedures on animals must receive training for these tasks. When students or trainees use animals in educational activities or for the advancement of science, such work shall be conducted under the direct supervision of an experienced teacher, investigator, or veterinarian.

---